story of the week
Empagliflozin Improves Cardiovascular and Renal Outcomes in Patients With Heart Failure
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Circulation
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status — Results From the EMPEROR-Reduced Trial
Circulation 2020 Nov 11;[EPub Ahead of Print], SD Anker, J Butler, G Filippatos, MS Khan, N Marx, CSP Lam, S Schnaidt, AP Ofstad, M Brueckmann, W Jamal, E Bocchi, P Ponikowski, SV Perrone, JL Januzzi, S Verma, M Böhm, JP Ferreira, SJ Pocock, F Zannad, M PackerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.